Literature DB >> 32931743

Immunogenomic Landscape of Hematological Malignancies.

Olli Dufva, Petri Pölönen, Oscar Brück, Mikko A I Keränen, Jay Klievink, Juha Mehtonen, Jani Huuhtanen, Ashwini Kumar, Disha Malani, Sanna Siitonen, Matti Kankainen, Bishwa Ghimire, Jenni Lahtela, Pirkko Mattila, Markus Vähä-Koskela, Krister Wennerberg, Kirsi Granberg, Suvi-Katri Leivonen, Leo Meriranta, Caroline Heckman, Sirpa Leppä, Matti Nykter, Olli Lohi, Merja Heinäniemi, Satu Mustjoki.   

Abstract

Entities:  

Year:  2020        PMID： 32931743     DOI： 10.1016/j.ccell.2020.08.019

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  8 in total

Review 1.  Application of Single-Cell Approaches to Study Myeloproliferative Neoplasm Biology.

Authors:  Daniel Royston; Adam J Mead; Bethan Psaila
Journal:  Hematol Oncol Clin North Am       Date:  2021-04       Impact factor: 3.722

Review 2.  CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia.

Authors:  Oren Pasvolsky; May Daher; Gheath Alatrash; David Marin; Naval Daver; Farhad Ravandi; Katy Rezvani; Elizabeth Shpall; Partow Kebriaei
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

3.  Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia.

Authors:  Jani Huuhtanen; Dipabarna Bhattacharya; Tapio Lönnberg; Matti Kankainen; Cassandra Kerr; Jason Theodoropoulos; Hanna Rajala; Carmelo Gurnari; Tiina Kasanen; Till Braun; Antonella Teramo; Renato Zambello; Marco Herling; Fumihiro Ishida; Toru Kawakami; Marko Salmi; Thomas Loughran; Jaroslaw P Maciejewski; Harri Lähdesmäki; Tiina Kelkka; Satu Mustjoki
Journal:  Nat Commun       Date:  2022-04-11       Impact factor: 17.694

4.  NAIRscore as a biomarker for the quality of immune response to neoantigens is related with an increased overall survival in multiple myeloma.

Authors:  Xingxing Jian; Linfeng Xu; Jingjing Zhao; Yanhui Wang; Wen Zhou; Lu Xie
Journal:  Mol Ther Nucleic Acids       Date:  2022-07-12       Impact factor: 10.183

5.  A comprehensive study of alternative splicing in malignant pleural mesothelioma identifies potential therapeutic targets in a new cluster with poor survival.

Authors:  Ming-Ming Shao; Xin Qiao; Qing-Yu Chen; Feng-Shuang Yi
Journal:  Thorac Cancer       Date:  2022-07-05       Impact factor: 3.223

6.  Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia.

Authors:  François Vergez; Laetitia Largeaud; Sarah Bertoli; Marie-Laure Nicolau; Jean-Baptiste Rieu; Inès Vergnolle; Estelle Saland; Audrey Sarry; Suzanne Tavitian; Françoise Huguet; Muriel Picard; Jean-Philippe Vial; Nicolas Lechevalier; Audrey Bidet; Pierre-Yves Dumas; Arnaud Pigneux; Isabelle Luquet; Véronique Mansat-De Mas; Eric Delabesse; Martin Carroll; Gwenn Danet-Desnoyers; Jean-Emmanuel Sarry; Christian Récher
Journal:  Blood Cancer J       Date:  2022-08-16       Impact factor: 9.812

Review 7.  Current status and future perspectives in targeted therapy of NPM1-mutated AML.

Authors:  Roberta Ranieri; Giulia Pianigiani; Sofia Sciabolacci; Vincenzo Maria Perriello; Andrea Marra; Valeria Cardinali; Sara Pierangeli; Francesca Milano; Ilaria Gionfriddo; Lorenzo Brunetti; Maria Paola Martelli; Brunangelo Falini
Journal:  Leukemia       Date:  2022-08-25       Impact factor: 12.883

8.  Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients.

Authors:  Kristiina Karihtala; Suvi-Katri Leivonen; Marja-Liisa Karjalainen-Lindsberg; Fong Chun Chan; Christian Steidl; Teijo Pellinen; Sirpa Leppä
Journal:  Blood Adv       Date:  2022-03-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.